Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2020-02-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于公司独立董事辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of an independent director from the company's board. It discusses the resignation letter, the impact on the board composition, and the process for appointing a new independent director. There is no financial data, no mention of financial results, no regulatory certifications, or report publications. The content clearly relates to changes in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is short and focused solely on this management change, confirming the classification.
2020-02-19 Chinese
独立董事对第四届董事会第三次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of certain matters to be discussed at the company's fourth board meeting. It references compliance with regulatory guidelines and internal company rules, and it specifically addresses a related-party transaction to be submitted for board approval. The document is short (757 characters) and does not contain financial statements or detailed financial data. It is not a full report but rather a governance-related statement or certification related to board meeting matters. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management matters, including approvals and opinions related to board meetings.
2020-02-11 Chinese
关于召开2020年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2020 first extraordinary general meeting of shareholders for 瑞康医药集团股份有限公司. It includes information about the meeting time, location, voting procedures (both onsite and online), agenda items for shareholder approval, registration details, and proxy authorization forms. There is no financial data or results reported, nor is there a transcript or presentation. The document is an official announcement informing shareholders about the meeting and how to participate and vote on specific proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length (5350 characters) and content confirm it is the meeting notice and proxy information, not the voting results or minutes. Therefore, the correct classification is PSI with high confidence.
2020-02-11 Chinese
第四届监事会第三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at the third meeting of the fourth Supervisory Board of Ruikang Pharmaceutical Group Co., Ltd. It details the approval of a guarantee proposal for subsidiaries and mentions the voting results. The document is short (831 characters) and serves as a formal announcement of a board/management decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion but focuses on a governance-related decision. Therefore, it fits best under Board/Management Information (MANG).
2020-02-11 Chinese
独立董事对第四届董事会第三次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the company's fourth board meeting, specifically regarding guarantees for subsidiaries and related party transactions. It references compliance with laws and regulations, board procedures, and approval for submission to the shareholders' meeting. The content is focused on board/management governance and opinions rather than financial results, audit, or regulatory filings. The document length is short (1319 characters) and does not contain financial statements or detailed financial data. It is not an announcement of a report but a formal board-related opinion document. Therefore, the most appropriate classification is Board/Management Information (MANG).
2020-02-11 Chinese
关于为全资及控股子公司提供担保及对公司已担保额度进行减少的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 瑞康医药集团股份有限公司 (Ruikang Pharmaceutical Group Co., Ltd.) regarding guarantees provided for its wholly-owned and controlled subsidiaries, including adjustments to guarantee limits. It includes extensive tables listing guarantee amounts, relationships between guarantors and guaranteed parties, purposes of guarantees, and financial data of the guaranteed entities. The content focuses on corporate financing activities related to guarantees and credit support for subsidiaries, rather than financial results, management changes, or legal proceedings. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a simple announcement of a report publication but a substantive disclosure about capital/financing activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-02-11 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.